Table 5.
Treatment group | Low | Medium | High | |||
---|---|---|---|---|---|---|
Baseline (n = 32) | Week 12 (n = 32) | Baseline (n = 35) | Week 12 (n = 32) | Baseline (n = 28) | Week 12 (n = 23) | |
Genistein (ng/ml) | 10.01 ± 22.07a | 82.75 ± 124.62A | 9.83 ± 24.25 | 168.71 ± 166.81B | 6.40 ± 9.27 | 216.71 ± 305.36B |
Daidzein (ng/ml) | 5.03 ± 11.88 | 20.44 ± 30.82A | 2.29 ± 4.37 | 39.20 ± 36.9B | 2.50 ± 3.34 | 49.82 ± 66.49B |
Equol (ng/ml) | 1.76 ± 6.01 | 3.81 ± 8.17A | BLD | 9.43 ± 19.84A | 0.42 ± 1.30 | 11.69 ± 19.23A |
BLD below limit of detection
aMean ± SD (all such values)
A,BValues with different superscript letters across a row are significantly different (Kruskal–Wallis with post hoc Mann–Whitney U test)